Um Estudo de Fase 2A de uma Nova Pirrolidinamida Antimalárica em Doentes Adultos com Malária Não Complicada por P. Falciparum
Um Estudo de Fase 2A para Avaliar a Segurança, Tolerabilidade e Farmacocinética de uma Nova Pirrolidinamida Antimalárica em Diferentes Doses e Durações de Dose, em Doentes Adultos com Malária Não Complicada por P. Falciparum
The study will evaluate the safety and efficacy of a new antimalarial drug GSK3772701 (a pyrrolidinamide), using different doses and treatment durations, in adult participants with uncomplicated Plasmodium (P.) falciparum malaria.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 2
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
Estude backup de contato
- Nome: EU GSK Clinical Trials Call Center
- Número de telefone: +44 (0) 20 89904466
- E-mail: GSKClinicalSupportHD@gsk.com
Locais de estudo
-
-
-
Lambaréné, Gabão
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Rella Zoleko Manego
-
-
-
-
Tororo
-
Kampala, Tororo, Uganda, 749
- Recrutamento
- GSK Investigational Site
-
Contato:
- US GSK Clinical Trials Call Center
- Número de telefone: 877-379-3718
- E-mail: GSKClinicalSupportHD@gsk.com
-
Contato:
- EU GSK Clinical Trials Call Centre
- Número de telefone: +44 (0) 20 8990 4466
- E-mail: GSKClinicalSupportHD@gsk.com
-
Investigador principal:
- Adoke Yeka
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Male and female patients aged 18 to 65 years.
-
Presence of malaria due to mono-infection with P. falciparum confirmed by:
- Fever, as defined by axillary temperature >=37.5°C or oral/tympanic temperature >=38°C and,
- Microscopically confirmed P. falciparum malaria parasite mono-infection,
- A parasite count between 2,000 to 60,000 asexual parasite count/µL of blood for P. falciparum.
-
Have a BMI between >=18 and <=30 kg/m2.
-
Able to swallow oral medication.
-
Signed informed consent, acknowledging understanding and willingness to comply with the requirements of the study. If the patient is unable to write, thumb print consent, signed by an impartial witness is permitted according to local ethical considerations.
-
Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
-
A female participant is eligible to participate if she is not pregnant or breastfeeding, and one of the following conditions applies:
- Is a woman of non-childbearing potential (WONCBP) or
- Is a woman of childbearing potential (WOCBP) and using an acceptable contraceptive method, from Study Day 1, and during the study intervention period (40 +/-3 days).
Exclusion Criteria:
- Patients with signs and symptoms of severe/complicated malaria according to the WHO 2024 Criteria.
- Mixed Plasmodium infection, i.e., infection with more than one malaria (plasmodium) species (by microscopy; participant to be withdrawn from study treatment if PCR subsequently indicates presence of mixed infection).
- Abnormal values: QTcF >450 msec or QTcF >480 msec for patients with bundle branch block.
- Any clinically significant ECG abnormalities at Screening unrelated to malaria (including but not limited to, second degree AV block (Mobitz Type 2), complete heart block, ST changes, atrial fibrillation, atrial flutter, supraventricular tachycardia, ventricular tachycardia, prolonged QT interval.
- History of malignancy (or current malignancy) of any organ system (other than localized carcinoma of the skin), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases.
- Creatinine >=2 x ULN.
- Significant illness within two weeks prior to screening.
- Positive HIV antibody test at screening, or history of HIV infection based on past positive test result, clinical record or current treatment.
- Severe vomiting, defined as more than 3 times in the 24 hours before screening or inability to tolerate oral treatment.
- Severe diarrhoea defined as more than 3 watery stools per day in the 24 hours before screening.
- Known history or evidence (based on clinical examination or investigation) of uncontrolled active cardiovascular disease (including hypertension), respiratory disease (including active tuberculosis even if treatment is ongoing), liver cirrhosis or liver disease (based on prior investigation, clinical signs and/or interpretation of liver enzymes), other active hepatic, renal, gastrointestinal, immunological, neurological, endocrine, infectious, or psychiatric disease.
- Anaemia (Hb <=8.0g/dl) or known clinically important chronic underlying haematological disease such as sickle cell disease at screening.
- Significant chronic medical conditions which in the opinion of the investigator preclude enrolment into the study.
- Have received any antimalarial treatment in the preceding 6 weeks (see Section 6.10), as determined by history or medical record.
- Prior enrolment in this study and receipt of treatment with GSK3772701.
- Use of other investigational drugs at the time of enrolment, or within 6 weeks, or 5 half-lives prior to enrolment into this study, whichever is longer; or longer if required by local regulations, and for any other limitation of participation in an investigational trial based on local regulations.
- History of hypersensitivity to the study drug or drug formulation and capsule (Hypromellose (hydroxypropyl methylcellulose)) constituents.
- History of drug or alcohol abuse within 3 months prior to dosing, or clinical evidence of such abuse.
- Participants who in the opinion of the Investigator are unsuitable for participation in the study or cannot be enrolled due to logistical reasons.
- ALT >2.0 x ULN.
- Total bilirubin >1.5 x ULN; Participants with Gilbert's syndrome can be included with total bilirubin >1.5xULN as long as direct bilirubin is <=1.5xULN.
- Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
- Presence of hepatitis B surface antigen (HBsAg) at screening or within 3 months prior to first dose of study intervention.
- Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention.
Note: Participants with positive hepatitis C antibody due to prior resolved disease can be enrolled, only if a confirmatory negative Hepatitis C RNA test is obtained.
• Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention.
Note: Test is optional and participants with negative Hepatitis C antibody test are not required to also undergo Hepatitis C RNA testing.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Cohort 1_Single Dose
Participants receive a single GSK3772701 600 mg dose on Day 1. |
A 600 mg dose of GSK3772701 administered orally, as 4 capsules of 150 mg. |
|
Experimental: Cohort 2_ Single Dose
Participants receive a single GSK3772701 900 mg dose on Day 1. |
A 900 mg dose of GSK3772701 administered orally, as 6 capsules of 150 mg. |
|
Experimental: Cohort 3_ Repeat Dose
Participants receive a daily 150 mg dose of GSK3772701 on Day 1 and Day 2. |
A daily 150 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 1 capsule. |
|
Experimental: Cohort 4_ Repeat Dose
Participants receive a daily 400 mg dose of GSK3772701 on Day 1 and Day 2. |
A daily 400 mg dose of GSK3772701 administered orally on Day 1 and Day 2, as 2 capsules of 150 mg and 1 capsule of 100 mg. |
|
Experimental: Cohort 5_ Repeat Dose
Participants receive a daily 50 mg dose of GSK3772701 on Day 1, Day 2 and Day 3. |
A daily 50 mg dose of GSK3772701 administered orally on Day 1, Day 2 and Day 3, as 1 capsule. |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Number of participants with serious adverse events (SAEs) overall, treatment related, and by severity
Prazo: From the date of informed consent signing (up to 24 hours prior to Day 1) up to Day 40 (end of the follow-up period)
|
A SAE is defined as any untoward medical occurrence that, at any dose: results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant; abnormal pregnancy outcomes; or any other situation according to medical or scientific judgment. The intensity of SAEs is assessed as per the Division of Acquired Immunodeficiency Syndrome (DAIDS) criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity. Any = occurrence of the event regardless of intensity grade and treatment relationship. Treatment related = occurrence of the event which, in the investigator's opinion, is related to the administered treatment regardless of the intensity grade. |
From the date of informed consent signing (up to 24 hours prior to Day 1) up to Day 40 (end of the follow-up period)
|
|
Number of participants with non-serious AEs overall, treatment related, and by severity
Prazo: From Day 1 up to Day 40
|
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. The intensity of non-serious AEs is assessed using the DAIDS criteria Version 2.1 where grades are defined based on numeric criteria as follows Grade 1: mild; Grade 2: moderate; Grade 3: severe; Grade 4: potentially life-threatening; Grade 5: death. A higher grade indicates greater severity. Any = occurrence of the event regardless of intensity grade and treatment relationship. Treatment related = occurrence of the event which, in the investigator's opinion, is related to the administered treatment regardless of the intensity grade. |
From Day 1 up to Day 40
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Concentração máxima observada (Cmax) de GSK3772701
Prazo: Do Dia 1 ao Dia 7
|
Do Dia 1 ao Dia 7
|
|
|
Area under the concentration (AUC) - time curve (AUC[0-t]) of GSK3772701
Prazo: From Day 1 to Day 7
|
AUC(0-t) is defined as the area under the concentration-time curve from time zero to the time of the last evaluable concentration. |
From Day 1 to Day 7
|
|
AUC(0-t) extrapolated to infinity (AUC[0-inf]) of GSK3772701
Prazo: From Day 1 to Day 7
|
AUC(0-inf) is defined as the area under the concentration-time curve extrapolated to infinity calculated as: . AUC(0-inf) = AUC(0-t) + C(t) / λz. |
From Day 1 to Day 7
|
|
Time to maximum observed drug concentration (Tmax) of GSK3772701
Prazo: From Day 1 to Day 7
|
Tmax is defined as time to reach the Cmax. |
From Day 1 to Day 7
|
|
Apparent terminal half-life (t1/2) of GSK3772701
Prazo: From Day 1 to Day 7
|
Apparent terminal phase half-life in plasma (and blood), calculated as loge (2)/λz. |
From Day 1 to Day 7
|
|
Trough concentration (Ctau) of GSK3772701 following multiple dose administration
Prazo: From Day 2 to Day 7
|
Ctau is defined as the trough/pre-dose concentration after dosing interval, tau. |
From Day 2 to Day 7
|
|
Observed accumulation ratio (R) of GSK3772701 for AUC [AUC(Ro)] following multiple dose administration
Prazo: From Day 2 or Day 3 to Day 7, compared to Day 1
|
AUC-tau (Ro) is defined as the accumulation ratio for AUC(0-tau) comparing last day of dosing to Day 1. |
From Day 2 or Day 3 to Day 7, compared to Day 1
|
|
Observed accumulation ratio of GSK3772701 based on Cmax (RCmax) following multiple doses
Prazo: From Day 2 or Day 3 to Day 7, compared to Day 1
|
Cmax (RCmax) is defined as the accumulation ratio for Cmax comparing last day of dosing to Day 1. |
From Day 2 or Day 3 to Day 7, compared to Day 1
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- 223257
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer tohttps://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf
Prazo de Compartilhamento de IPD
Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.
Critérios de acesso de compartilhamento IPD
Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- CSR
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .